ARS Pharmaceuticals's total assets for Q2 2025 were $313.47M, a decrease of -4.23% from the previous quarter. SPRY total liabilities were $121.15M for the fiscal quarter, a 23.19% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.